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cense.Abstract Introduction: Bone metabolism may be uncoupled in postmenopausal rheumatoid
arthritis (RA). Osteoporotic fracture in RA is highest for the hip especially in elderly women.
Aim of the work: To detect the bone mineral density (BMD) and markers of bone turnover in
postmenopausal RA patients and study the inﬂuence of age at disease onset. Correlation with
clinical and laboratory manifestations and disease activity were considered.
Patients and methods: Sixty postmenopausal RA patients were recruited into two groups, group
I: 30 elderly onset (EORA) and group II: 30 young onset (YORA) patients. Thirty age and sex
matched healthy subjects served as control. Full history taking, clinical examination, relevant inves-
tigations including calcium, phosphorus, total alkaline phosphatase (ALP), bone speciﬁc alkaline
phosphatase (BALP), osteocalcin (OC), and N-terminal cross-linked telopeptides of type I collagen
(NTX) were measured and BMD assessed by DEXA in all patients and control. Disease activity
score in 28 joints (DAS-28) was calculated.foura Square, Mokattam City,
: +20 225085372.
(T. Gheita).
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156 T. Gheita et al.Results: The NTX was remarkably increased and the BMD decreased in RA patients. Osteocal-
cin in RA was 3.87 ± 1.15 ng/ml being obviously lower in EORA patients compared to YORA and
control. In EORA, a signiﬁcant correlation was present between the ALP and OC (r 0.41, p 0.025)
and the NTX and BALP (r 0.46, p 0.011) and a negative correlation between the hip BMD and
DAS-28 (r 0.43, p 0.019).
Conclusion: Impaired bone formation and uncoupling of bone turnover are more evident in post-
menopausal EORA patients which form a risk predictor of fracture hip in this subgroup of patients.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Population-growth in the elderly and the development of new
therapeutic agents for rheumatoid arthritis (RA) contributes to
an increase in the number of elderly patients with RA. Elderly-
onset RA (EORA) is deﬁned as RA developing after the age of
60 years [1,2]. With the increasing life expectancy, osteoporosis
is becoming a major worldwide health problem being larger in
developing countries including Egypt where the prevalence of
low bone mass is increased with a very high prevalence of vita-
min D insufﬁciency. Even in a sunny country, hypovitaminosis
D is common which is probably explained by a low intake [3].
Little is known about the differences in the immunopathogen-
esis between EORA and younger-onset RA (YORA) and the
factors responsible for their clinical characteristics [4]. At sim-
ilar disease duration, EORA differs from YORA by a more
balanced gender distribution, a higher frequency of acute onset
and systemic features, more frequent involvement of the shoul-
der girdle and higher disease activity [1,5]. In EORA, the dis-
ease phenotype is changed compared to YORA highlighting
the importance of aging on the immune system [6]. Cause
and effect of comorbid diseases such as osteoporosis and car-
diovascular disease are points of interest especially in EORA
[7].
Osteoporosis is a systemic disease characterized by compro-
mised bone mass and strength, predisposing to an increased
risk of fracture [8]. One in 3 women older than 50 years will
eventually experience osteoporotic fractures [9]. While the level
of bone mass can be estimated by measuring bone mineral den-
sity (BMD) using dual energy X-ray absorptiometry (DEXA),
its measurement does not capture all the risk factors for frac-
ture. Quantitative changes in skeletal turnover can be assessed
easily and non-invasively by the measurement of serum and
urinary biochemical markers; the most sensitive markers in-
clude serum osteocalcin (OC) and bone speciﬁc alkaline phos-
phatase (BALP) for bone formation and the cross linked N-
telopeptides of type I collagen (NTX) for bone resorption
[10]. In postmenopausal osteoporosis, abnormal levels of bone
markers are associated with an increased risk of fracture. The
combined use of BMD measurement and biochemical markers
is helpful in risk assessment [10]. Any process that increases the
rate of bone remodeling, results in net bone loss over time [11].
Furthermore, in periods of rapid remodeling, as postmeno-
pause, bone is at an increased risk for fracture because the
newly produced bone is less densely mineralized, the resorption
sites are temporarily unﬁlled, and the isomerization and matu-
ration of collagen is impaired [12].
Markers of bone formation as OC and ALP are important
for promoting vulnerability to hip fracture [13,14]. Bone
metabolism may be uncoupled in chronic RA and bone forma-tion appears to be reduced, partly reﬂecting disease activity,
whereas resorption is increased only in steroid users in post-
menopausal RA patients [15]. Changes in the levels of bone
turnover markers may reﬂect fracture risk and therapeutic
success even before changes in BMD become apparent [16].
Alkaline phosphatase lacks sensitivity and speciﬁcity for oste-
oporosis, because it can be elevated or decreased with many
diseases and is increased with aging [16]. In adults with normal
liver function, approximately 50% of total ALP activity arises
from the liver and 50% from bone. The development of bone-
speciﬁc ALP improved speciﬁcity and sensitivity; however,
changes in BALP can lag by several weeks [17]. Serum markers
of bone resorption are useful measures in postmenopausal
osteoporosis, especially NTX which shows lower variability
among patients [18], is the best marker for assessing the bone
metabolic state and is the best predictor for the rate of bone
loss or fracture risk [19].
The aim of the present study was to detect the BMD and
markers of bone turnover; bone formation (OC and ALP both
total and bone speciﬁc) and bone resorption (serum NTX) and
correlate the ﬁndings with clinical manifestations, laboratory
ﬁndings and disease activity in elderly and younger onset RA
patients in order to ﬁnd a possible impact of the age of disease
onset on osteoporosis.
2. Patients and methods
Sixty postmenopausal RA patients were included in the cur-
rent study with deﬁnite RA diagnosed according to the 2010
ACR/EULAR classiﬁcation criteria for RA [20] attending
the Rheumatology and orthopedic surgery outpatient clinics
of Cairo University Hospitals. Patients were recruited into
two groups, group I included 30 elderly onset and group II,
30 young onset RA. Patients who had concurrent medical con-
ditions known to affect bone metabolism (including renal or li-
ver disease, malignancy, thyroid or other endocrine disorders)
were excluded. All the patients were veiled house wives that
were not sufﬁciently exposed to the sun and not receiving
any vitamin D supplementation. Full history taking, thorough
examination, laboratory and relevant radiological investiga-
tions as well as DEXA were performed for all patients. The
diagnosis of osteoporosis was based on the World Health
Organization criteria [21] for osteoporosis. BMD was quanti-
ﬁed by DEXA (lunar, prodigy 10041) at lumbar level (L2–
L4), at the hip level (femoral neck and total hip) and at the dis-
tal forearm (distal radius and ulna). Data were obtained for
BMD (g/cm2), T score (deviation with respect to peak bone
mass) and Z score (deviation with respect to age-matched nor-
mal values). Complete blood count, Erythrocyte sedimentation
rate (ESR), total serum calcium, phosphorus, total alkaline
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of bone turnover; markers of bone formation: Osteocalcin
(OC) and bone-speciﬁc alkaline phosphatase (BALP) and
markers of bone resorption: N-terminal crosslinked telopep-
tides of type I collagen (NTX) were measured in all patients.
Disease activity score, in 28 joints (DAS-28), was calculated
[22]. The functional status was assessed according to the
1991 ACR revised criteria for the classiﬁcation of global func-
tional status in RA [23]. Thirty age matched postmenopausal
healthy subjects were included in the study as control. All
the laboratory investigations and DEXA were also performed
for the control subjects.
Morning blood samples were withdrawn and serum osteo-
calcin was determined with a commercially available radioim-
munoassay kit (INCSTAR corporation-Stillwater, Minnesota,
USA). The normal level in the studied control averaged
7.3 ± 1.67 ng/ml. Serum Bone speciﬁc Alkaline phosphatase
was measured by Enzyme Immunoassay kit (ALKPHASE-B,
Metra Biosystem, Mountain View, CA) [24] and the normal le-
vel in the studied control averaged 23.07 ± 3.12 lg/L) accord-
ing to the method described in a previous study. Serum marker
of bone resorption; N-terminal crosslinked telopeptides of type
I collagen (NTX) was measured by chemiluminescence assay in
competitive inhibition method [Osteomark NTx Serum, Wam-
pole Laboratories, Inc., NJ, USA] [25]. Normal level of serum
NTX in the present study control averaged 15.82 ± 3.59 nmol/
L of bone collagen equivalents (BCE). All laboratory measure-
ments were performed in chemical pathology department,
Cairo University Hospital Laboratories. The study was ap-
proved by the local ethical committee.
Statistics: The data were collected, tabulated and analysed
by SPSS package version 15 (SPSS corporation, USA). Data
was summarized as mean ± SD. Mann–Whitney tests was
used for comparative analysis of 2 quantitative data.
Non-parametric analysis of variance (Kruskall–Wallis) was
used for comparison of more than two groups; Spearman’s
correlation analysis was used for detection of the relationTable 1 Demographic and clinical features of the elderly and youn
Demographic features RA patients
(Mean ± SD) EORA (30)
Age (years) 64.13 ± 2.7
Age at onset (years) 62.13 ± 1.74
Disease duration (years) 2.05 ± 2.04
BMI 24.86 ± 3.38
Morning Stiﬀness (min) 64.0 ± 30.92
Functional class 2.93 ± 1.01
DAS-28 3.47 ± 0.37
Clinical features (%)
Subcutaneous nodules 4 (13.33)
Flexor tendon nodules 21 (70)
Trigger ﬁnger 2 (6.67)
Carpal tunnel syndrome 3 (10)
Frozen Shoulder 1 (3.33)
Sjogren’s syndrome 1 (3.33)
Dry eyes 2 (6.67)
Dry mouth 4 (13.33)
X-ray Hand erosions 20 (66.67)
MTP J erosions 1 (3.33)
EORA: elderly onset rheumatoid arthritis, YORA: younger onset rheuma
28, MTP J: metatarsophalangeal joints.between two variables. Results were considered signiﬁcant at
p< 0.05.3. Results
Sixty postmenopausal RA patients were included in the cur-
rent study (group I, 30 EORA and group II, 30 YORA).
The mean age of the patients was 62.45 ± 8.26 years. At dis-
ease onset, the small joints of the hands were most affected
in EORA (80%) and YORA (63.33%), followed by the knees
(13.33%) in both age onsets. The worst joints affected at the
time of the study were the knees (40%) and hands (40% in
EORA and 30% in YORA) followed by the ankles (13.33%)
in YORA and the shoulders (10%) in both disease onsets.
Other demographic, clinical, laboratory and DEXA investiga-
tions of the two groups are shown in Tables 1 and 2. The con-
trol subjects were age matched (62.33 ± 6.08 years) with the
patients (p 0.94) with a body mass index (BMI) of 27.51 ±
6.04. None of the patients were smoking.
The DAS-28 was signiﬁcantly higher in the EORA patients
(p 0.000). Patients were not receiving any corticosteroids one
year before the study. However, all patients gave a past history
of corticosteroid intake which was either of low dose oral pred-
nisolone or infrequent methylprednisolone intramuscular
injections during severe ﬂares. All were receiving Methotrexate
12.5–17.5 mg/week in combination with hydroxychloroquine
in 45 patients, azathioprine in 5 and leﬂunomide in another
10 patients. Five of the patients were receiving a combination
of MTX, hydroxychloroquine and leﬂunomide. NSAIDs were
received by all the patients. None of the patients were receiving
any treatment for osteoporosis except irregular intake of cal-
cium without any vitamin D.
The mean OC level in all the RA patients was 3.87 ±
1.15 ng/ml being lower in EORA patients compared to the
control (p 0.000). All the patients and control had normal liver
function enzymes AST, ALT and GGT. The BMD asg onset postmenopausal RA patients.
Sig.
YORA (30) p
60.77 ± 11.21 0.12
49.08 ± 5.11 0.000
14.32 ± 5.29 0.000
26.11 ± 4.11 0.2
65.83 ± 49.74 0.86
2.47 ± 0.97 0.07
3.00 ± 0.38 0.000
5 (16.67)
12 (40)
1 (3.33)
2 (6.67)
1 (3.33)
0 (0)
1 (3.33)
1 (3.33)
9 (30)
1 (3.33)
toid arthritis, BMI: body mass index, DAS-28: disease activity index-
Table 2 Laboratory and DEXA ﬁndings of the elderly and young onset RA postmenopausal patients and control.
Laboratory ﬁndings (Mean ± SD) Control RA patients Sig.
EORA (30) YORA (30) p
ESR (1st h/mmHg) 30.37 ± 13.87 60.37 ± 28.11 52.43 ± 24.79 0.000
Hb (g%) 13.1 ± 1.2 11.15 ± 1.69* 12.43 ± 1.16 0.000
Platelet (·103/mm3) 290.37 ± 68.57 343.73 ± 131.01 327.93 ± 88.1 0.11
WBC (·103/mm3) 6.78 ± 2.55 7.26 ± 3.08 7.97 ± 2.16 0.22
Calcium (mg/dl) 9.34 ± 0.77 9.02 ± 0.65 9.25 ± 0.82 0.23
Phosphorus (mg/dl) 4.49 ± 0.92 4.25 ± 0.97 4.33 ± 0.99 0.63
ALP (U/L) 167 ± 50.68 154.97 ± 61.87 177.2 ± 67.88 0.37
BALP 23.07 ± 3.12 18.29 ± 7.15 24.91 ± 3.07 0.000
Osteocalcin (ng/ml) 7.3 ± 1.67 3.33 ± 0.74* 4.41 ± 1.24 0.000
NTX 15.82 ± 3.59 28.58 ± 6.23 26.93 ± 5.23 0.000
DEXA (T score)
Spine 1.3 ± 0.55 2.52 ± 1.01 1.81 ± 0.85 0.000
Hip 1.2 ± 0.61 2.61 ± 1.23 2.19 ± 1 0.000
Radius 1.22 ± 0.4 2.22 ± 0.99 2.28 ± 1.22 0.000
EORA: elderly onset rheumatoid arthritis, YORA: younger onset rheumatoid arthritis, DEXA: dual energy X-ray absorptiometry, ESR:
erythrocyte sedimentation rate, Hb: hemoglobin, WBC: white blood cells, ALP: alkaline phosphatase, BALP: bone speciﬁc ALP, NTX: N-
terminal crosslinked telopeptides of type I collagen.
* Signiﬁcantly different from the corresponding value at p< 0.05.
158 T. Gheita et al.measured by DEXA was signiﬁcant decreased in all the RA
patients compared to the postmenopausal control (p 0.001).
The signiﬁcant results are demonstrated in Fig. 1.
On comparing the results of the EORA and YORA pa-
tients, rheumatoid factor was positive in 70% of both groups
while Anti-CCP was positive in 80% of EORA and 66.67%
of YORA patients. There was a signiﬁcant difference in the
hemoglobin level (p 0.001) and markers of bone formation;
(BALP p 0.000, OC 0.000) while there was a non signiﬁcant
difference of the ESR, platelet, WBC count, ALP, calcium,
phosphorus and the marker of bone resorption (NTX) (p
0.27). Furthermore, the BMD did not signiﬁcantly differ
between the EORA and YORA patients in the spine (p
0.21), radius (p 0.094) and hip (p 0.31). Severe osteoporosisFigure 1 Serum osteocalcin and BMD of the hip in elderly and y
different from the corresponding result in YORA patients and controwith a high risk of fragility fracture was more in the EORA pa-
tients in the hip (60%) spine (66.67%) and radius (46.67%) of
patients while it was present in the hip and spine in 40% and
20% respectively in YORA patients. Osteopenia was present
in the hip (26.67%), spine (23.33%) and radius (43.33%) of
EORA patients and in 50%, 43.33% and 66.67% respectively
in YORA. Normal BMD in EORA was present in the hip in
13.33%, spine and radius in 10%. In YORA patients, normal
BMD was present in the hip in 10%, the spine in16.67% and
the radius in 13.33% of YORA patients.
Correlation of the markers of bone turn over with the demo-
graphic, clinical, laboratory and DEXA ﬁndings in the studied
patients are shown in Tables 3 and 4. In EORA patients, the
functional class negatively correlated with the calcium level (roung onset RA patients compared to control. H= signiﬁcantly
l at p< 0.05.
Table 3 Correlation of markers of bone formation with demographic and clinical features in elderly and young onset RA patients.
Demographic and clinical features r (p) EORA YORA
OC ALP BALP OC ALP BALP
Age 0.15 (0.42) 0.19 (0.32) 0.002 (0.99) 0.14 (0.48) 0.12 (0.54) 0.26 (0.18)
Age at onset 0.26 (0.17) 0.21 (0.28) 0.054 (0.78) 0.26 (0.16) 0.05 (0.78) 0.005 (0.98)
Disease duration 0.04 (0.84) 0.05 (0.78) 0.017 (0.93) 0.49* (0.006) 0.1 (0.61) 0.19 (0.31)
BMI 0.25 (0.18) 0.36 (0.051) 0.41* (0.026) 0.2 (0.3) 0.008 (0.97) 0.13 (0.51)
DAS-28 0.51* (0.004) 0.42* (0.02) 0.21 (0.27) 0.16 (0.4) 0.41* (0.03) 0.18 (0.34)
Morning stiﬀness 0.14 (0.47) 0.25* (0.18) 0.23 (0.23) 0.13 (0.49) 0.11 (0.58) 0.1 (0.59)
Functional class 0.13 (0.49) 0.04 (0.83) 0.07 (0.72) 0.13 (0.5) 0.11 (0.58) 0.16 (0.39)
EORA: elderly onset rheumatoid arthritis, YORA: younger onset rheumatoid arthritis, OC: osteocalcin, ALP: alkaline phosphatase, BALP:
bone-speciﬁc alkaline phosphatase.
* Signiﬁcant correlation at p< 0.05. BMI: Body mass index, DAS-28: Disease activity index-28.
Table 4 Correlation of markers of bone formation with laboratory and DEXA features in elderly and young onset RA patients.
Laboratory and DEXA features r (p) EORA YORA
OC ALP BALP OC ALP BALP
ESR (1st h/mmHg) 0.47* (0.009) 0.34 (0.07) 0.1 (0.6) 0.11 (0.57) 0.21 (0.91) 0.26 (0.16)
Hb (g%) 0.2 (0.29) 0.005 (0.98) 0.29 (0.13) 0.18 (0.33) 0.07 (0.71) 0.16 (0.4)
Platelet (·103/mm3) 0.21 (0.27) 0.24 (0.2) 0.24 (0.2) 0.38* (0.04) 0.18 (0.34) 0.14 (0.48)
WBC (·103/mm3) 0.31 (0.1) 0.22 (0.25) 0.3 (0.1) 0.21 (0.27) 0.2 (0.3) 0.13 (0.5)
Calcium (mg/dl) 0.08 (0.67) 0.24 (0.2) 0.21 (0.27) 0.1 (0.6) 0.1 (0.61) 0.15 (0.42)
Phosphorus (mg/dl) 0.18 (0.34) 0.15 (0.42) 0.11 (0.56) 0.005 (0.98) 0.24 (0.19) 0.24 (0.2)
NTX 0.24 (0.2) 0.34 (0.07) 0.46* (0.011) 0.25 (0.19) 0.01 (0.97) 0.048 (0.8)
DEXA (T score)
Spine 0.31 (0.1) 0.35 (0.06) 0.3 (0.85) 0.46* (0.01) 0.03 (0.86) 0.02 (0.9)
Hip 0.56* (0.001) 0.24 (0.2) 0.06 (0.11) 0.19 (0.31) 0.2 (0.28) 0.17 (0.36)
Radius 0.28 (0.13) 0.04 (0.86) 0.04 (0.85) 0.44* (0.02) 0.07 (0.72) 0.01 (0.95)
EORA: elderly onset rheumatoid arthritis, YORA: younger onset rheumatoid arthritis, DEXA: dual energy X-ray absorptiometry, ESR:
erythrocyte sedimentation rate, Hb: hemoglobin, WBC: white blood cells, OC: osteocalcin, ALP: alkaline phosphatase, BALP: bone speciﬁc
ALP, NTX: N-terminal crosslinked telopeptides of type I collagen.
* Signiﬁcant correlation at p< 0.05.
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with the total ALP (r 0.41, p 0.025) but not with the BALP (r
0.17, p 0.37), while the BMD of the spine signiﬁcantly nega-
tively correlated with the age (r 0.48, p 0.008) and ESR
(0.38, p 0.04) and the hip signiﬁcantly negatively correlated
with the DAS-28 (r 0.43, p 0.019). In YORA patients, there
was no signiﬁcant correlation of OC with total ALP (r 0.26,
p 0.17) or BALP (r 0.05, p 0.79). Fig. 2 shows demonstrates
the correlation between OC and the BMD T score of the hip
in EORA and spine and radius in YORA. The combination
of BMD and bone turnover measurement allows the identiﬁca-
tion of women at a much higher risk for hip fracture. Regarding
the marker of bone resorption (NTX), in the EORA
patients, there was a signiﬁcant negative correlation with the
BMD of the radius (r 0.37, p 0.043) and hip (r 0.38,
p 0.039) as well as with the BMI (r 0.68, p 0.000). While in
YORA patients, it signiﬁcantly correlated with the serum
phosphorus (r 0.38, p 0.039).
4. Discussion
An impact of the age at disease onset in RA on osteoporosis
was veriﬁed in the results of the present study. The bone
metabolism was examined using bone densitometry and mark-
ers of bone turnover were studied and correlated with clinicalmanifestations, laboratory ﬁndings and disease activity in el-
derly and younger onset RA patients. Osteoporosis is identi-
ﬁed as a common dilemma in RA patients. Prevention of
bone and cartilage destruction is the most important goal in
its treatment, but it has never been completely achieved by
conventional drug therapy, whose main target is the suppres-
sion of inﬂammation. Knowledge of the mechanisms involved
in bone loss is still limited and evidence is now accumulating
rapidly to suggest that osteoclastic activation, rather than sup-
pression of bone formation, is the dominant process in bone
destruction in RA [26]. Bone loss was particularly increased
in RA patients with active disease, low levels of physical activ-
ity and glucocorticoid treatment and was responsible for an in-
creased risk and rates of hip and vertebral fractures [27,28].
Decreased BMD, increased bone resorption, and normal or re-
duced bone formation have been demonstrated in RA patients
[29].
In the present study, there was a great reduction in BMD of
the hip and spine, a signiﬁcant increase in bone resorption
marker (NTX) in all RA patients while the markers of bone
formation, BALP and OC, were more signiﬁcantly reduced
among the EORA postmenopausal compared to the YORA
patients and control. In postmenopausal RA, osteopenia was
suggested to be caused by an uncoupling of bone formation
and resorption, and disease activity induces a high turnover
Figure 2 Correlation between the serum osteocalcin with the BMD hip in EORA and with spine and radius in YORA.
160 T. Gheita et al.[15]. Reduced markers of bone formation and remodeling in
postmenopausal women is in agreement with other studies
[15,30]. It should also be taken into consideration that the
age at disease onset is a main risk factor for development of
osteoporosis in RA patients especially as the decreased BMD
and reduced markers of bone formation were more evident
in EORA than those found in YORA patients although the
disease duration was much longer in the latter. Reduced OC/
BALP ratio could be clinically useful for assessing impaired
bone formation and the risk of vertebral fractures independent
of BMD [31]. The bone turnover marker levels are inﬂuenced
by several factors; they moderately correlate with BMD and
subsequent bone loss and risk of fracture [32]. The patients
in the present study were not receiving corticosteroids for
one year before the study and all were using DMARDs. This
study was not designed to evaluate the possible contribution
of corticosteroids as a cause of secondary osteoporosis.
In the present study, OC signiﬁcantly negatively correlated
with disease activity in the EORA and ALP negatively corre-
lated with DAS-28 in both EORA and YORA patients. Fur-
thermore in EORA, the hip BMD negatively correlated with
DAS-28. In another study, disease activity has been shown
to be a determinant of BMD in RA patients and together with
functional impairment contributed to bone loss, especially in
the proximal femur [33,34]. Rheumatoid patients with active
disease lost more bone at the spine and hip than inactive pa-
tients [27].
In the current study, osteopenia and reduced bone mass
were found more often at the level of the hip than at the spine,
which may reﬂect a higher risk of hip fracture in EORA pa-
tients. Furthermore, reduced BMD at the hip signiﬁcantly cor-
related with the reduced OC. In agreement with these results
was the signiﬁcant increased frequency of reduced bone mass
at the hip in RA patients [29]. In RA, periarticular bone loss,
bone erosions and osteoporosis are observed, with anincreased risk of fractures. Other determinants of fracture in
RA include the female preponderance and an increased preva-
lence with age, severity of the disease, and use of glucocorti-
coids. However, bone loss can occur even in glucocorticoid-
naive patients [35]. The incidence for osteoporotic fracture
among RA patients was highest for hip fracture being higher
in women and increased with older age [36]. Moreover, in a co-
hort study on Japanese RA patients, 86% were at high risk for
hip fracture [37].
In our study, the marker of bone resorption (NTX) was
highly elevated in the RA patients without any signiﬁcant dif-
ference between EORA and YORA which may suggest that
the increased bone resorption is not the main cause for the
obvious uncoupling of bone turnover seen in EORA. Further-
more, the NTX signiﬁcantly correlated with BALP and nega-
tively with the radius and hip BMD only in EORA patients.
In EORA, the balance between bone resorption and formation
was maintained between the NTX and BALP and lost between
NTX and OC. A possible explanation for the disharmony in
the relation of NTX with BALP and OC is that changes in
BALP lags the reduction in OC [17].
The clinical features showed that EORA patients had more
manifestations, extraarticular presentation, joint erosions and
osteoporosis as well as a higher disease activity than YORA.
In congruence, EORA patients appear to have differences in
clinical characteristics and a higher frequency of comorbidities
[4] and a higher disease activity and severity [38]. In our study,
after exclusion of PMR cases, the shoulder was found to be
equally involved as in YORA patients although the disease
duration was much longer in the latter. In agreement with this
ﬁnding, other studies showed that there was a signiﬁcantly
higher frequency of shoulder involvement and disease activity
in EORA patients compared to YORA of the same disease
duration[5,39,40]. A progression of X-ray erosions despite sec-
ond line drug treatment was found in both EORA and YORA
Impaired bone formation and osteoporosis in postmenopausal elderly onset rheumatoid arthritis patients 161patients, especially in EORA suggesting that treatment ap-
proaches used in classical YORA should be instituted with
equal vigor in patients with EORA [41]. The functional class
was worse in EORA in the present study. In a similar study,
EORA was associated with a 6-fold risk of functional disabil-
ity [42]. In this study, anti-CCP antibodies were higher in the
EORA patients. Similarly, anti-CCP was more associated with
extra-articular manifestations and radiological damage in
EORA [43]. The optimal control of inﬂammation in RA is
associated with decrease in structural damage and bone loss.
Rheumatoid arthritis illustrates the role of inﬂammation on
bone resorption [35]. Recently, researchers try to study the
importance of the balance in the cytokines and the RANKL-
RANK-osteoprotegerin system in postmenopausal RA
patients [44].
In conclusion, the age at disease onset should be taken into
consideration when evaluating RA comorbidities and manag-
ing EORA patients. The obviously reduced BMD and im-
paired bone formation are responsible for the imbalanced
bone turnover in EORA. Osteocalcin and alkaline phospha-
tase signiﬁcantly inversely correlated with disease activity espe-
cially in the EORA patients. The BMD measurement and
potential utility of sensitive bone turnover biomarkers are
needed in predicting the risk of fracture hip especially in post-
menopausal EORA patients. This would emphasis on the role
of administrating bone forming medications in EORA and
stress on the intake of calcium supplements and vitamin D
as part of the treatment regimen for RA patients.
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